Eli Lilly to acquire Bothell’s Curevo Vaccine for $1.5 billion
The Seattle Times • • business
Key Points:
- Eli Lilly announced plans to acquire Curevo Vaccine, a Bothell-based biotech company developing vaccines for shingles and chickenpox, for $1.5 billion; the deal is pending customary closing conditions.
- The acquisition is part of three agreements revealed by Lilly, which also plans to buy U.S.-based Vaccine Company for $1.6 billion and Switzerland’s LimmaTech Biologics for $780 million.
- Lilly, known for drugs like Prozac, Cialis, and weight loss medications Zepbound and Foundayo, recently reported positive clinical trial results for another weight loss drug, retatrutide.
- Curevo's lead product candidate, amezosvatein, is expected to benefit from Lilly’s global development and commercialization expertise, according to Curevo CEO George Simeon.